The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases.

The deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing ...

These stocks have jumped in the double- and triple-digits.

Crinetics stock nearly doubled late Monday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company.

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Morgan Stanley said the recent weakness in U.S. semiconductor stocks is a sign that the market gains are broadening, with ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...

The stock was up 39% to $2.25 in late Tuesday morning trading. The shares are now down less than 1% in the past 52 weeks. Farokhzad, who is also the biotechnology company's chair, made the unsolicited ...

Morgan Stanley says U.S. equity-market leadership is beginning to expand beyond the semiconductor and AI infrastructure ...

Morgan Stanley’s pivot is from “chip winners” to hyperscalers with AI infrastructure optionality. MSFT has the strongest mix ...

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

Hyperscalers may benefit as chip stocks struggle, according to Morgan Stanley strategists. The once-hot semiconductor trade has seen a cooling in the last couple of weeks, which is not only likely to ...